Vaginal Candidiasis More Likely With Realworld Use Of Sglt2 Inhibitors Vs Clinical Trials | Latest News RSS feed

Vaginal Candidiasis More Likely With Realworld Use Of Sglt2 Inhibitors Vs Clinical Trials - Latest News


Fungal Infections With New Diabetes Drugs 'Manageable'

Whether this proves to be the case once the SGLT2 inhibitors are in widespread clinical use remains to be seen ... genital mycotic infections were more likely to have a history of vulvovaginitis (29% ... read more

Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth

This sample size provided the trial with more than 99% power for the outcome of blood loss of at least 500 ml or the use of ... with likely biases and differences in doses, administration routes, and ... read more

SGLT2 Inhibitors Side Effects

SGLT2 inhibitors ... are vaginal yeast infections, yeast infections of the penis, stuffy or runny nose, and changes in urination. These common side effects occurred in two percent or more of clinical ... read more

Looking for another news?


Bolstering your armamentarium with SGLT2 inhibitors

Data from clinical trials of SGLT2 ... enzyme inhibitors, or angiotensin receptor blockers. 26-28 Managing adverse reactions. Glucosuria creates an environment conducive to vaginal mycotic infections ... read more


SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives

Keywords: type 2 diabetes mellitus, GLP-1 receptor agonist, SGLT2 inhibitor, A1c, weight loss, adverse effect A Medline search was performed in August 2015 to identify clinical trials and ... read more

Real-World Evidence Shows Oral INVOKANA® 300 mg Demonstrates Comparable A1C Reduction and Control to Injectable GLP-1 Receptor Agonists

1 Patients on INVOKANA ® were also less likely to discontinue their medication or be prescribed a new antihyperglycemic agent (AHA). These findings with INVOKANA ®, a sodium glucose co-transporter 2 ... read more

Janssen Presents New Data Showing INVOKANA® (canagliflozin) is Associated with ...

For the RW analysis, the investigators matched patients taking INVOKANA ® (624 patients) with those taking a DPP-4 inhibitor (603 patients) based on demographics and initial clinical characteristics . ... read more

Real-World Evidence Shows Oral INVOKANA® 300 mg Demonstrates Comparable A1C Reduction and Control to Injectable GLP-1 Receptor Agonists

[1] Patients on INVOKANA [®] were also less likely to discontinue their medication or be prescribed a new antihyperglycemic agent (AHA). These findings with INVOKANA [®] , a sodium glucose ... read more

An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes

In the few years attending this new class arrival in the market, there has been a great deal of interest generated by the novel mechanism of action of SGLT2 inhibitors and by recent large outcome ... read more

Interpreting Geographic Variations in Results of Randomized, Controlled Trials

Clinical trialists generally accept the premise ... On the one hand, even when a treatment is truly beneficial, trials in some countries with few participants are more likely to show a point estimate ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us